Download Special Issue
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cardioactive Agents : Metoprolol, Sotalol and Milrinone. Influence of Myocardial Content and Systolic Interval
3Õ' î'qt ACUTE HAEMODYNAMIC EFFECTS OF THREE CARDIOACTIVE AGENTS : METOPROLOL, SOTALOL AND MILRINONE. INFLUENCE OF MYOCARDIAL CONTENT AND SYSTOLIC INTERVAL. by Rebecca Helen Ritchie, B.Sc (Hons) A thesis submitted for the degree of Doctor of Philosophy ln The University of Adelaide (Faculty of Medicine) February 1994 Department of Medicine (Cardiology Unit, The Queen Elizabeth Hospital) The University of Adelaide Adelaide, SA, 5000. ll ¡ r -tL',. r,0';(', /1L.)/'t :.: 1 TABLE OF CONTENTS Table of contents 1 Declaration vtl Acknowledgements v111 Publications and communications to learned societies in support of thesis D( Summary xl Chapter 1: General Introduction 1 1.1 Overview 2 1.2 Acute effeots of cardioactive drugs 3 1.2.1 Drug effects 4 l.2.2Determnants of drug effects 5 1.3 Myocardial drug gPtake of cardioactive agents 8 1.3.1 Methods of assessment in humans invívo 9 1.3.2 Results of previous studies 10 1.4Influence of cardioactive drugs on contractile state 11 1.4. 1 Conventional indices 11 I.4.2 The staircase phenomenon t2 1.4.3 The mechanical restitution curve t2 1.5 The present study t4 1.5.1 Current relevant knowledge of the acute haemodynamic effects of the cardioactive drugs under investigation r4 1.5.1.1 Metoprolol 15 1.5.1.2 Sotalol 28 1.5.1.3 Milrinone 43 1.5.2 Cunent relevant knowledge of the short-term pharmacokinetics of the cardioactive drugs under investigation 59 1.5.2.1Metoprolol 59 1.5.2.2 Sotalol 7I ll 1.5.2.3 Milrinone 78 1.5.3 Current relevant knowledge of the potential for rate-dependence of the effects of these -
Genome 559 Intro to Statistical and Computational Genomics
Genome 559! Intro to Statistical and Computational Genomics! Lecture 16a: Computational Gene Prediction Larry Ruzzo Today: Finding protein-coding genes coding sequence statistics prokaryotes mammals More on classes More practice Codons & The Genetic Code Ala : Alanine Second Base Arg : Arginine U C A G Asn : Asparagine Phe Ser Tyr Cys U Asp : Aspartic acid Phe Ser Tyr Cys C Cys : Cysteine U Leu Ser Stop Stop A Gln : Glutamine Leu Ser Stop Trp G Glu : Glutamic acid Leu Pro His Arg U Gly : Glycine Leu Pro His Arg C His : Histidine C Leu Pro Gln Arg A Ile : Isoleucine Leu Pro Gln Arg G Leu : Leucine Ile Thr Asn Ser U Lys : Lysine Ile Thr Asn Ser C Met : Methionine First Base A Third Base Ile Thr Lys Arg A Phe : Phenylalanine Met/Start Thr Lys Arg G Pro : Proline Val Ala Asp Gly U Ser : Serine Val Ala Asp Gly C Thr : Threonine G Val Ala Glu Gly A Trp : Tryptophane Val Ala Glu Gly G Tyr : Tyrosine Val : Valine Idea #1: Find Long ORF’s Reading frame: which of the 3 possible sequences of triples does the ribosome read? Open Reading Frame: No stop codons In random DNA average ORF = 64/3 = 21 triplets 300bp ORF once per 36kbp per strand But average protein ~ 1000bp So, coding DNA is not random–stops are rare Scanning for ORFs 1 2 3 U U A A U G U G U C A U U G A U U A A G! A A U U A C A C A G U A A C U A A U A C! 4 5 6 Idea #2: Codon Frequency,… Even between stops, coding DNA is not random In random DNA, Leu : Ala : Tryp = 6 : 4 : 1 But in real protein, ratios ~ 6.9 : 6.5 : 1 Even more: synonym usage is biased (in a species dependant way) Examples known with 90% AT 3rd base Why? E.g. -
Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells
Int. J. Mol. Sci. 2015, 16, 5572-5589; doi:10.3390/ijms16035572 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells Cheng-Fang Tsai 1,†, Yueh-Hsiung Kuo 1,2,†, Wei-Lan Yeh 3, Caren Yu-Ju Wu 4, Hsiao-Yun Lin 5, 4 4 4 1 5,6, Sheng-Wei Lai , Yu-Shu Liu , Ling-Hsuan Wu , Jheng-Kun Lu and Dah-Yuu Lu * 1 Department of Biotechnology, Asia University, Taichung 413, Taiwan; E-Mails: [email protected] (C.-F.T.); [email protected] (Y.-H.K.); [email protected] (J.-K.L.) 2 Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan 3 Department of Cell and Tissue Engineering, Changhua Christian Hospital, Changhua 500, Taiwan; E-Mail: [email protected] 4 Graduate Institute of Basic Medical Science, College of Medicine, China Medical University, Taichung 404, Taiwan; E-Mails: [email protected] (C.Y.-J.W.); [email protected] (S.-W.L.); [email protected] (Y.-S.L.); [email protected] (L.-H.W.) 5 Graduate Institute of Neural and Cognitive Sciences, China Medical University, Taichung 404, Taiwan; E-Mail: [email protected] 6 Department of Photonics and Communication Engineering, Asia University, Taichung 413, Taiwan † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-4-2205-3366 (ext. 8206); Fax: +886-4-2207-1507. Academic Editor: Guido R. -
WO 2Ull/13162O Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 1 / A 1 27 October 2011 (27.10.2011) WO 2Ull/13162o Al (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, C12N 9/02 (2006.01) A61K 38/44 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, A61K 38/17 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/EP20 11/056142 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 18 April 201 1 (18.04.201 1) SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Langi English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 10160368.6 19 April 2010 (19.04.2010) EP ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicants (for all designated States except US): MEDI- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, FT, LT, LU, ZINISCHE UNIVERSITAT INNSBRUCK [AT/AT]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Christoph-Probst-Platz, Innrain 52, A-6020 Innsbruck SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (AT). -
Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany). -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Ijphs Jan Feb 07.Pmd
www.ijpsonline.com Review Article Pharmacogenomics and Computational Genomics: An Appraisal P. K. TRIPATHI*, SHALINI TRIPATHI AND N. K. JAIN1 Rajarshi Rananjay Sinh College of Pharmacy, Amethi-227 405, 1Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar-470 003, India. Pharmacogenomics deals with the interactions of individual genetic constitution with drug therapy. It is very likely that pharmacogenetic tests will make up a significant proportion of total molecular biology testing in future. Therefore, this article emphasizes the applications of pharmacogenomics, and computational genome analysis in drug therapy. Patients sometimes experience adverse drug reactions for both efficacy and safety of a given drug regimen and (ADR) leading to deterioration of their underlying this is the central topic of pharmacogenomics. Drug condition in clinical practice. Physiology of individual development and pretreatment genetic analysis of patients patient can vary, so the response of an individual to drug will be two major practical aspects in pharmacogenomics. therapy may also be highly variable. This is a major Highly specialized drug research laboratories will achieve clinical problem, since this inter-individual variability is the first goal, while the second goal has to be achieved until now only partly predictable. Besides these medical by clinical .com).laboratories 2,3. problems, cost-benefit calculations for a given pharmacological therapy will be affected significantly. Drug development: This is exemplified by a recent US study, which estimates There are two pharmacogenomic approaches. First, for that over 100,000 patients die every year from ADRs1. most therapies a correct diagnosis is mandatory for a satisfactory therapeutic result. This is more relevant There are many factors such as age, sex, nutritional.medknow because many diseases may be caused by different status, kidney and liver function, concomitant diseases and genetic defects or be significantly affected by the genetic medications, and the disease that affects drug responses. -
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M
- + ! ,' Br. J. Pharmac. (1978), 64, 293-300. F'(O t.,," e reab- ,ellular PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC _-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM 1978) G.M. Departmentof Pharmacology,Allen and HzmburysResearchLimited, Ware, Hertfordshire,SG12 ODJ I The presynaptic ct-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to at-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ! ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch i response; the maximum inhibition obtained was 80 to 95_o of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 lag/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine. -
Exploring Autophagy with Gene Ontology
Autophagy ISSN: 1554-8627 (Print) 1554-8635 (Online) Journal homepage: https://www.tandfonline.com/loi/kaup20 Exploring autophagy with Gene Ontology Paul Denny, Marc Feuermann, David P. Hill, Ruth C. Lovering, Helene Plun- Favreau & Paola Roncaglia To cite this article: Paul Denny, Marc Feuermann, David P. Hill, Ruth C. Lovering, Helene Plun- Favreau & Paola Roncaglia (2018) Exploring autophagy with Gene Ontology, Autophagy, 14:3, 419-436, DOI: 10.1080/15548627.2017.1415189 To link to this article: https://doi.org/10.1080/15548627.2017.1415189 © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. View supplementary material Published online: 17 Feb 2018. Submit your article to this journal Article views: 1097 View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=kaup20 AUTOPHAGY, 2018 VOL. 14, NO. 3, 419–436 https://doi.org/10.1080/15548627.2017.1415189 RESEARCH PAPER - BASIC SCIENCE Exploring autophagy with Gene Ontology Paul Denny a,†,§, Marc Feuermann b,§, David P. Hill c,f,§, Ruth C. Lovering a,§, Helene Plun-Favreau d and Paola Roncaglia e,f,§ aFunctional Gene Annotation, Institute of Cardiovascular Science, University College London, London, UK; bSIB Swiss Institute of Bioinformatics, Geneva, Switzerland; cThe Jackson Laboratory, Bar Harbor, ME, USA; dDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, UK; eEuropean Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, Cambridge, UK; fThe Gene Ontology Consortium ABSTRACT ARTICLE HISTORY Autophagy is a fundamental cellular process that is well conserved among eukaryotes. It is one of the Received 18 May 2017 strategies that cells use to catabolize substances in a controlled way. -
Cytogenetic Analysis of a Pseudoangiomatous Pleomorphic/Spindle Cell Lipoma
ANTICANCER RESEARCH 37 : 2219-2223 (2017) doi:10.21873/anticanres.11557 Cytogenetic Analysis of a Pseudoangiomatous Pleomorphic/Spindle Cell Lipoma IOANNIS PANAGOPOULOS 1, LUDMILA GORUNOVA 1, INGVILD LOBMAIER 2, HEGE KILEN ANDERSEN 1, BODIL BJERKEHAGEN 2 and SVERRE HEIM 1,3 1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 2Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 3Faculty of Medicine, University of Oslo, Oslo, Norway Abstract. Background: Pseudoangiomatous pleomorphic/ appearance’ (1). To date, only 20 patients have been described spindle cell lipoma is a rare subtype of pleomorphic/spindle in the literature with this diagnosis, 15 of whom were males cell lipoma. Only approximately 20 such tumors have been (1-10). The pseudoangiomatous pleomorphic/spindle cell described. Genetic information on pseudoangiomatous lipomas were mostly found in the neck (seven patients) and pleomorphic/spindle cell lipoma is restricted to a single case shoulders (four patients), but have also been seen in the in which deletion of the forkhead box O1 (FOXO1) gene was cheek, chest, chin, elbow, finger, subscapular region, and found, using fluorescence in situ hybridization (FISH). thumb. Genetic information on pseudoangiomatous Materials and Methods: G-banding and FISH analyses were pleomorphic/ spindle cell lipoma is restricted to one case only performed on a pseudoangiomatous pleomorphic/spindle cell (8) in which fluorescence in situ hybridization (FISH) with a lipoma. Results: G-banding of tumor cells showed complex probe for the forkhead box O1 ( FOXO1 ) gene, which maps karyotypic changes including loss of chromosome 13. FISH to chromosome sub-band 13q14.11, showed a signal pattern analysis revealed that the deleted region contained the RB1 indicating monoallelic loss of the gene in 57% of the gene (13q14.2) and the part of chromosome arm 13q (q14.2- examined cells. -
ECM Alterations in Fndc3a (Fibronectin Domain Containing
www.nature.com/scientificreports OPEN ECM alterations in Fndc3a (Fibronectin Domain Containing Protein 3A) defcient zebrafsh Received: 22 April 2019 Accepted: 5 September 2019 cause temporal fn development Published: xx xx xxxx and regeneration defects Daniel Liedtke 1, Melanie Orth1, Michelle Meissler1, Sinje Geuer2,3, Sabine Knaup1, Isabell Köblitz1,4 & Eva Klopocki 1 Fin development and regeneration are complex biological processes that are highly relevant in teleost fsh. They share genetic factors, signaling pathways and cellular properties to coordinate formation of regularly shaped extremities. Especially correct tissue structure defned by extracellular matrix (ECM) formation is essential. Gene expression and protein localization studies demonstrated expression of fndc3a (fbronectin domain containing protein 3a) in both developing and regenerating caudal fns of zebrafsh (Danio rerio). We established a hypomorphic fndc3a mutant line (fndc3awue1/wue1) via CRISPR/ Cas9, exhibiting phenotypic malformations and changed gene expression patterns during early stages of median fn fold development. These developmental efects are mostly temporary, but result in a fraction of adults with permanent tail fn deformations. In addition, caudal fn regeneration in adult fndc3awue1/wue1 mutants is hampered by interference with actinotrichia formation and epidermal cell organization. Investigation of the ECM implies that loss of epidermal tissue structure is a common cause for both of the observed defects. Our results thereby provide a molecular link between these developmental processes and foreshadow Fndc3a as a novel temporal regulator of epidermal cell properties during extremity development and regeneration in zebrafsh. A wide number of conserved genetic and structural features have been identifed regulating fn development in ray fnned fsh species, like zebrafsh (Danio rerio), and imply shared mechanisms throughout evolution1.